Analysis of SGM 597, a flurbiprofen derivative, on breast cancer cell lines: effects on cell proliferation and apoptosis

Abstract

Purpose and Background: Breast cancer is a growing health concern, particularly among females. Researchers are
concentrating on finding new medications that help combat breast cancer. There is a striking degree of biological
similarity between breast cancer and prostate cancer. Accordingly, the 4-(4-chlorophenyl)-3-(1-(2-fluoro-[1,1'-
biphenyl]-4-yl)ethyl), 5-((4-fluorobenzyl)thio)Research using the MCF-7 and MCF-10A breast cancer and mammary
epithelial cell lines examined the effects of the chemical SGK597, which inhibits cell growth in prostate cancer.
Methods: To find out if SGK597 was cytotoxic or viable in MCF-7 and MCF10-A cell lines, the WST-8 technique
was used. We used the JC-1 test to find out whether the potential across the mitochondrial membrane changed.
Western blot analysis was used to evaluate the amounts of apoptosis-associated proteins, including Bax, Bcl-2, and cPARP.
The IC50 values for MCF-7 were 28.74 μM and 17.28 μM after 24 hours of incubation with SGK597, while for MCF10A, they were 65.9 μM and 50.5 μM, respectively. While MCF-10A cells did not exhibit a trend toward
depolarization of the mitochondrial membrane potential in response to increasing concentrations of SGK597, MCF-7
cells did. No rise in the Bax/Bcl-2 ratio or c-PARP expression level was seen in western blot tests, suggesting the
absence of apoptosis.
Results showed that SGK597 inhibited the growth of MCF-7 cells. These findings suggest that SGK597 might be an
effective anticancer drug.